Michael J. Sofia

This profile gathers the share dealings of Michael J. Sofia in Arbutus Biopharma Corp, where the filings describe the role as chief executive. The record holds 3 filings, for trades running from 1 December 2021 to 1 February 2024.

Sales make up the whole of the open-market record (1 sale, €898k). Outside the open market, there are 2 share grants.

On 5 February 2024 came the latest disclosure, a share grant in Arbutus Biopharma Corp. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.